Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat in Malignant Mesothelioma
NCT03319537Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pevonedistat in malignant mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2017; status: terminated.
02
Drugs
pevonedistat
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03319537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319537.